Epitalon Dosage Guide: Protocols from Russian Research to Modern Practice

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide based on the active sequence of epithalamin — the natural polypeptide extract from bovine pineal glands studied extensively by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology from the 1970s onward. The dosing protocols in current use derive almost entirely from this 40+ year research programme, making Epitalon unusual among research peptides in having a reasonably consistent historical dosing record. This guide translates that record into practical protocol guidance.

Standard Research Dosing

The most consistently used Epitalon doses across the Russian research literature are:

• 5 mg/day: The most common dose in human trials and elderly cohort studies. Used in the 12-year longevity study. Associated with melatonin normalisation, immune function improvement, and cardiovascular mortality reduction.
• 10 mg/day: Used in some intensive protocols and primate studies. Produces similar qualitative effects to 5 mg with potentially stronger initial telomerase activation signal in some models.
• Higher doses (20–50 mg/day): Tested in some preclinical studies but not shown to produce proportionally greater benefits than 5–10 mg. The dose-response curve for Epitalon appears relatively flat above 5 mg, suggesting receptor saturation at modest doses.

Subcutaneous vs Intravenous Administration

Both subcutaneous and intravenous routes have been used in research, with different contexts:

• Subcutaneous injection: Standard route for outpatient research and clinical protocols. Reliable bioavailability for a tetrapeptide of Epitalon's size. Most accessible and practical for research applications outside hospital settings.
• Intravenous (slow infusion): Used in some hospital-based Russian protocols for older patients where injection compliance was a consideration. Provides immediate systemic exposure but requires clinical infrastructure. Not standard for typical research protocols.
• Intranasal: Explored in some protocols for convenience. Limited data on bioavailability compared to injectable routes; generally considered inferior to subcutaneous for systemic endpoints.

Course Structure and Daily Timing

A standard Epitalon course uses daily injection for 10 consecutive days. Key timing considerations:

• Morning administration: Some protocols prefer morning dosing to align with natural cortisol and pineal signalling rhythms.
• Evening administration: Evening dosing aligns with the melatonin-producing role of the pineal gland and may more directly influence nocturnal melatonin secretion patterns — the endpoint most readily measurable in short-term studies.
• The published data does not definitively favour morning vs evening for primary endpoints (telomere length, immune markers). Both protocols have been used successfully.

Age-Specific Dosing Considerations

The majority of Epitalon human data is from older adults (55+) where telomerase activity and melatonin production are naturally declining. This shapes the dosing context:

• Older adults (55+): Most responsive to Epitalon's telomerase and melatonin effects due to baseline deficiency — the 5 mg/day standard dose is well-supported for this population.
• Middle-aged adults (35–55): Less data; effects on melatonin and immune markers are measurable but smaller in magnitude given baseline levels are closer to normal. Some protocols use the same 5 mg dose; others suggest this group may be a primary candidate for preventive cycling protocols rather than restorative ones.
• Younger adults (<35): Minimal published data. Telomerase and melatonin are typically intact; biological signal from Epitalon administration may be smaller. Research protocols in this age group are limited.

The 12-Year Khavinson Longevity Study

The most frequently cited long-term Epitalon human data is Korkushko et al. (2006) — a 12-year observation of elderly subjects receiving periodic epithalamin (the natural precursor polypeptide, rather than synthetic Epitalon) courses. Key findings at 10-year follow-up included significantly reduced cardiovascular mortality, improved maintenance of sleep architecture, and sustained immune function indices compared to untreated controls. This dataset, while from the natural extract rather than synthetic Epitalon, informs the synthetic peptide's expected long-term research trajectory.

Frequently Asked Questions

Is 5 mg or 10 mg the better dose for research protocols?

5 mg/day is the most validated dose based on published human data. 10 mg/day is used when a stronger initial biological signal is desired or when the research subject has more advanced age-related decline. There is no clear evidence that 10 mg produces meaningfully superior outcomes in most endpoints studied.

Can Epitalon be reconstituted and stored for multiple-day use?

Reconstituted Epitalon should be stored at 2–8°C. Stability data specific to Epitalon is limited in the published literature, but standard peptide reconstitution guidance (refrigerated use within 4 weeks, avoid repeated freeze-thaw cycles) is applied in research practice.

What blood tests can confirm Epitalon's biological effects?

Melatonin (salivary or urinary) is the most readily measurable biomarker within a single 10-day course. Immune markers (NK cell activity, CD4/CD8 ratio) are assessable at 4–8 weeks post-course. Telomere length measurement (PCR-based) requires 3–6 months post-course to detect changes.

References

• Khavinson VKh, et al. (2001). Epitalon peptide induces telomerase activity and telomere elongation in human somatic cells. Neuroendocrinology Letters, 22(6), 417–423.
• Korkushko OV, et al. (2006). Normalizing effect of the pineal gland peptide preparation Epithalamin on the daily profile of melatonin in elderly subjects. Neuroendocrinology Letters, 27(1–2), 170–174.
• Anisimov VN, Khavinson VKh. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology, 11(2), 139–149.